Psychiatr. pro Praxi, 2006; 3: 117-121

Antimanic efficacy of second-generation antipsychotics

MUDr. Michal Maršálek CSc
Psychiatrická léčebna Bohnice, Praha

The evidence shows that second-generation antipsychotics are effective in the treatment of bipolar mania, either alone or in combination with traditional mood stabilisers. Use of second-generation antipsychotics is associated with more rapid symptom improvement than in mood stabilisers treatment, and earlier and stronger antimanic effect in combination with lithium or anticonvulsants than in monotherapy. Olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole demonstrate good therapeutic effect, with no significant differences in antimanic efficacy among these agents. Second-generation antipsychotics, lithium and valproate are recommended first-line treatments for acute bipolar mania.

Keywords: second-generation antipsychotics, bipolar mania, randomized double-blind trial

Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maršálek M. Antimanic efficacy of second-generation antipsychotics. Psychiatr. praxi. 2006;7(3):117-121.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry (Suppl) 2002; 159: 1-50.
    2. Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tohen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affect Dis 2003; 73: 147-153. Go to original source... Go to PubMed...
    3. Berk M, Ichim I, Brook S. Olanzapine compared to lithium in mania: a double-blind randomised controlled trial. Int Clin Psychopharmacology 1999; 14: 339-343. Go to original source... Go to PubMed...
    4. Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry; 2004, 65: 707-714. Go to original source... Go to PubMed...
    5. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-121. Go to original source... Go to PubMed...
    6. Carson WH, Sachs G, Sanchez R, et al. Aripiprazole vs. placebo for the treatment of acute mania in patients with bipolar disorder. Int Neuropsychopharmacol 2004; 7 (Suppl 1) Abs: 242.
    7. Davis JM, Chen N, Glick ID. A meta - analysis of the efficacy of second - generation antipsychotics. Arch Gen Psychiatry. 2003; 60: 553-564. Go to original source... Go to PubMed...
    8. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216-1223. Go to original source... Go to PubMed...
    9. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: Results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005; 66: 1116-1120. Go to original source... Go to PubMed...
    10. Herman E, Grof P, Hovorka J, Praško J, Doubek P. Bipolární porucha. In: Seifertová D, Praško J, Höschl C (eds). Postupy v léčbě psychiatrických poruch, Praha, Academia Medica Pragensis 2004: 93-126.
    11. Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebocontrolled trial. Am J Psychiatry 2004; 161: 1057-1065. Go to original source... Go to PubMed...
    12. Jones M & Huizar K. Quietiapine monotherapy for mania associated with bipolar disorder. Int J Psychiatry Clin Practice 2003; 7: 310-311, Abs P14.
    13. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, doubleblind, randomized trial. Am J Psychiatry 2003a; 160: 741-748. Go to original source... Go to PubMed...
    14. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003b; 160: 1651-1658. Go to original source... Go to PubMed...
    15. Khanna S, Vieta E, Lyons B, Grossman F, Kramer M. Risperidone in the treatment of acute bipolar mania: A double-blind, placebo-controlled study of 290 patients. Eur Neuropsychopharmacol 2003; 13 (Suppl 4): 314 Abs. Go to original source...
    16. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229-234. Go to original source... Go to PubMed...
    17. Kramer M, Karcher K, Grossman F. Risperidone monotherapy in acute bipolar mania. Eur Neuropsychopharmacol 2003; 13 (Suppl 4): 317 Abs. Go to original source...
    18. Maršálek M. Lékové profily: Risperidonum. Remedia 2001; 11: 364-383.
    19. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine and haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomized, prallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15: 573-585. Go to original source... Go to PubMed...
    20. McQuade R, Sanchez R, Marcus R, Carson W, Rollin L, Iwamoto T. Aripiprazole for relapse prevention in bipolar disorder in a 26-week trial. Int Neuropsychopharmacol 2004; 7 (Suppl 1) Abs: 160.
    21. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21: 389-397. Go to original source... Go to PubMed...
    22. Mullen J & Paulsson B. Quetiapine combined with lithium or divalproex for the treatment of acute mania associated with bipolar disorder. Int J Psychiatry Clin Practice 2003; 7: 311-312, Abs P17.
    23. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005; 25: 301-310. Go to original source... Go to PubMed...
    24. Ramey TS, Giller EE, English P. Efficacy and tolerability of ziprasidone in acute bipolar mania: 12-week double-blind study. Biol Psychiatry 2005; 5 Suppl Abst: 535.
    25. Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD004043. Go to original source... Go to PubMed...
    26. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146-1156. Go to original source... Go to PubMed...
    27. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213-223. Go to original source... Go to PubMed...
    28. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs TG, Breier A. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Dis 2003; 73: 155-161. Go to original source... Go to PubMed...
    29. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21: 176-180. Go to PubMed...
    30. Smulevič AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15: 75-84. Go to original source... Go to PubMed...
    31. Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RM, Keck PE Jr, Sachs GS, Crismon ML, Toprac MG, Shon SP; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002; 63: 288-299. Go to original source... Go to PubMed...
    32. Švestka J. Risperidon v neschizofrenních indikacích. Psychiatrie 2004; 8: 45-52.
    33. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702-709. Go to original source... Go to PubMed...
    34. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841-849. Go to original source... Go to PubMed...
    35. Tohen M, Zhang F, Feldman PD, Evans AR, Breier A. Olanzapine versus haloperidol in the treatment of acute mania. Bipolar Disord 2001a; 3: 61.
    36. Tohen M, Baker RW, Milton DR, Risser RC, Gilmore JA, Davis AR, Richey AL. Olanzapine versus divalproex sodium for the treatment of acute mania. Bipolar Disord 2001b; 3: 60. Go to original source...
    37. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002a; 159: 1011-1017. Go to original source... Go to PubMed...
    38. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002b; 59: 62-69. Go to original source... Go to PubMed...
    39. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218-1226. Go to original source... Go to PubMed...
    40. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood slabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345. Go to original source... Go to PubMed...
    41. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290. Go to original source... Go to PubMed...
    42. Tůma I & Chou JCY. Antipsychotika druhé generace v léčbě mánie. Psychiatrie 2004; 8: 54-61.
    43. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin 2005a; 21: 923-934. Go to original source... Go to PubMed...
    44. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T, on behalf of the Aripiprazole Study Group. Effectivenes of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br J Psychiatry 2005b; 187: 235-242. Go to original source... Go to PubMed...
    45. Weisler RH, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: A randomized, double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13 (Suppl 4): S344-S345 Abs. Go to original source...
    46. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry; 2003, 182: 141-147. Go to original source... Go to PubMed...
    47. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004; 24: 599-606. Go to original source... Go to PubMed...
    48. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, Beaulieu S, Daigneault A, Milev R, Young LT, Ravindran A, Schaffer A, Connolly M, Gorman CP; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3: 55-69. Go to original source... Go to PubMed...
    49. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148-1155. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.